

Research Platform Tool: Miniaturized Screening and Tailoring of Preclinical XR-Formulations for NCEs


MARCO BLOCK



INTEGRATING
Delivery Science
ACROSS DISCIPLINES



API-candidate-screening: Potential new **BLOCKBUSTER...**



...but

- ☐ rapid clearance or
- ☐ $c_{\text{sol}} > 25 \times \text{IC}_{50}$




require **tailored** XR-formulation
for Pharmacological
Proof-of-Concept (PPoC)

How to enable a certain c_{ss} with

- only **<< 1,000 mg of API** and
- **least** number of **animal** experiments



(1) Miniaturized formulation-tailoring



need for XR-formulation


cpd A

solubility (tissue medium)	0.043 µg/mL = 42 nM
IC ₅₀	0.24 nM
required RR in rat for 10-fold IC ₅₀	0.887 ng/d

☐ rapid clearance

☒ $c_{sol} > 25 \times IC_{50}$


„traditional“ approach



terminal RR at standard dose = 5.3 µg/d

☐ **6,000-fold >> required RR**

miniaturized screening



☐ ☒ **slightly higher dosed (x1.36) will enable 10-fold IC₅₀ for 28 d**

*all *in vitro* release data measured in triplicate and under sink conditions

(2) Prediction of pseudo c_{ss}

need for XR-formulation

cpd B


solubility (tissue medium)	36 $\mu\text{g/mL}$ = 87 μM
IC_{50}	60 nM
s.c. t_{max} / MRT	1 h / 3.6 h
required p_c for PPoC	1 μM for 24 h

☒ rapid clearance


☒ $c_{\text{sol}} > 25 \times \text{IC}_{50}$

☐ 28.6 mg/kg particles (20% DL) 1x/d will enable 1 μM

„traditional“ approach



IVIVC + p_c



*all *in vitro* release data measured in triplicate and under sink conditions

- ✓ Explore how limitations of downscaled spray drying can be surmounted
- ✓ Engage the use of established tool sequence to reduce animal experiments
- ☐ How exactly does the miniaturized spray dryer work?
- ☐ Are the miniaturized formulations stable and comparable?
- ☐ What if t_{rel} from initial screening is not sufficient?
- ☐ How to calculate $p_c c_{ss}$ / how does it translate *in vivo*?






Poster
Position
100







Background Article:






Marco Block, PhD Candidate
✉ marco.block@boehringer-ingenelheim.com
☎ +49 (7351) 54-177538










(1) Miniaturized formulation-tailoring



need for XR-formulation


cpd A

M_w	1028 g/mol
logD pH 2 / 11	4.1 / 4.2
solubility (tissue medium)	0.043 $\mu\text{g/mL}$ = 42 nM
IC_{50}	0.24 nM
required RR in rat for 10-fold IC_{50}	0.887 ng/d

☐ rapid clearance

☒ $c_{\text{sol}} > 25 \times IC_{50}$

„traditional“ approach




$$\text{terminal RR} = k_{\text{slow}} = 0.02210 \text{ h}^{-1}$$

terminal RR at standard dose = 5.3 $\mu\text{g/d}$

☐ 6,000-fold >> required RR

miniaturized screening



☒ PLGA low M_w ☐ **0.65 ng/d**
☒ PLA low M_w ☐ 0.022 ng/d
☒ PLA high M_w ☐ 0.017 ng/d

☐ **slightly higher dosed (x1.36)
will enable 10-fold IC_{50} for 28 d**

(2) Prediction of pseudo c_{ss}

need for XR-formulation

cpd B


M_w	412 g/mol
logD pH 2 / 11	1.2 / 1.8
solubility (tissue medium)	36 $\mu\text{g/mL}$ = 87 μM
IC_{50}	60 nM
s.c. t_{max} / MRT	1 h / 3.6 h

☒ rapid clearance

☒ Required $c_{ss} > 25 \times IC_{50}$ for PoC:

1 μM for 24 h

„traditional“ approach



terminal RR = $k_{slow}^{(in vitro)} = 0.1115 \text{ h}^{-1}$

$$pC_{ss} = \frac{k_0}{CL} = \frac{k_{slow} * \frac{D}{M_w}}{CL} \Leftrightarrow D = \left(\frac{pC_{ss} * CL}{k_{slow}} \right) * M_w = \left(\frac{0.001 \frac{\text{mmol}}{\text{L}} * 0.78 \frac{\text{L}}{\text{h} * \text{kg}}}{0.05620 \text{ h}^{-1}} \right) * 412 \frac{\text{mg}}{\text{mmol}} = 5.72 \frac{\text{mg}}{\text{kg}}$$

☐ 28.6 mg/kg particles (20% DL) 1x/d will enable 1 μM

IVIVC + pC_{ss}

